

Online Technical Meeting

Reinforcing HPV Vaccination and Cervical Cancer Screening and Treatment

15-16 April 2021

ANTWERP, BELGIUM

HPV Prevention and Control Board



www.hpvboard.org

Mission, Goal & Objectives

1. Mission:

Generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders.

2. Goal:

Contribute to the control of HPV infection and to the prevention and screening of HPV related cancers.

3. Objectives:

Providing evidence-based guidance on key technical and strategic issues.

Monitoring the progress of HPV control programs at the country and regional levels.



A multi-disciplinary Board formed by prominent experts (Advisors/Observers)

- Act in their personal capacity, and not as representatives of their institutions
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc : minimal bureaucratic structure
- Observers of several national and international organisations.



A multi-disciplinary Board formed by prominent experts

- Act in their personal capacity
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc : minimal bureaucratic structure

Advisors:

- Dr. Marc Arbyn, Scientific Institute of Public Health, Belgium
- Prof. dr. Paolo Bonanni, University of Florence, Italy
- Dr. Xavier Bosch, Catalan Institute of Oncology (ICO), Spain
- Dr. Kate Cuschieri, Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Scotland, UK
- Dr. Silvia de Sanjosé, Catalan Institute of Oncology (ICO), Spain
- Prof. dr. Eduardo Franco, McGill University, Canada
- Prof. Suzanne Garland, Australia
- Prof. Dr. Anna Giuliano, Moffitt Cancer Center, USA
- Dr. Mark Kane, Consultant, USA
- Dr. Sharon Hanley, Hokkaido University, Japan



A multi-disciplinary Board formed by prominent experts

Advisors:

- Prof. dr. Mira Kojouharova, National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria
- Prof. dr. Susanne Krüger Kjaer, University of Copenhagen, Denmark
- Dr. Heidi Larson, London School of Hygiene and Tropical Medicine, UK
- Prof. dr. Pier Luigi Lopalco, University of Pisa, Italy
- Prof. dr. Nubia Muñoz, Em. Prof of the National Cancer Institute of Colombia
- Prof. dr. Mario Poljak, Institute of Microbiology and Immunology, clinical Microbiology, Slovenia
- Prof. Dr. Margaret Stanley, University of

Cambridge, UK

- Prof. Dr. Pierre Van Damme, University of Antwerp, Belgium
- Dr. Alex Vorsters, University of Antwerp, Belgium
- Dr. Narendra Arora, India

Observers:

- Dr. Iacobo Baussano, IACR
- Dr. Nedret Emiroglu, WHO Euro
- Mr. Tarik Derrough, ECDC
- Dr. Liudmila Mosina , WHO Euro
- Dr. Lauri Markowitz, CDC, USA



Supported by a permanent & dynamic Scientific Secretariat:

- Personnel involved*:
 - Brenda Janssens, Xenia Mikulla
 - Greet Hendrickx
 - Sara Valckx
 - Dur-e-Nayab Waheed
 - Alex Vorsters
- Executive Secretary: Pierre Van Damme




- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp

*: Total involvement of 2.0 FTE, all member have other tasks at the department.



Secretariat implements:

- Preparation and organisation of meetings
 - Publications
 - Media activities
 - Website: www.hpvboard.org
 - Participation in third party meetings
 - All financial issues are done by the rules of the University of Antwerp
-  Permanent intensive communication between HPV board members and secretariat



HPV PREVENTION AND CONTROL BOARD

- About us
- Meetings
- Resources
- Vaccine safety
- News

HPV Prevention and Control Board



The HPV Prevention and Control Board was created in December 2015 with the aim to share relevant information on HPV with a broad array of stakeholders.

www.uantwerpen.be/en/projects/hpv-prevention-and-control-board/meetings/



HPV Prevention and Control Board Kick-Off meeting 1-2 December 2015



**Barriers in HPV Vaccination & cervical screening programmes.
27-28 June 2016 Meeting Antwerp:**



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward'
17-18 November 2016, Copenhagen, Denmark**




**Technical meeting: Symposium: Building Trust, Managing Risk:
Vaccine Confidence and Human Papillomavirus Vaccination,
7-8 June 2017, London, UK**



Country meeting: 'Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward'

30th November – 1 December 2017, Dublin, Ireland.



As the meeting was held in Dublin, we had the honour to have Mr Simon Harris, Minister of Health of Ireland, open the meeting. In his [speech](#), he reiterated his full support to the HPV vaccination programme in Ireland and emphasized the role of qualified medical professionals



**Technical meeting: Prevention and control of HPV and HPV related cancers: the role of HCW in the HPV vaccination and screening program implementation',
15 - 16 May 2018, Bucharest, Romania**



**Country meeting: 'Prevention and control of HPV and HPV related cancers in Colombia: lessons learnt and the way forward'
15-16 November 2018, Bogotá, Colombia**



**HPV Vaccination of Adults: Impact, Opportunities and Challenges.
14-15 November 2019, Antwerp, Belgium**

**Challenges in the HPV Screening Landscape, Triage of Screening
Positive Samples, and Screening in the Era of Vaccination.
27-28 August 2020, Antwerp, Belgium**

**Impact of COVID-19 on Cervical Cancer Screening, Treatment and
Vaccination.
12-13 November 2020, Antwerp, Belgium**



The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania, 15 & 16 May 2018

Short Videos



Benefits and Safety of HPV Vaccination
- Dr. Xavier Bosch



USA - Helping healthcare providers
improve HPV communication - Dr. Noel
Brewer



HPV Vaccination of Adults : Impact, Opportunities and Challenges. 14 & 15 Nov 2019

Videos



Potential Benefits of HPV Vaccine in sexually active women: delivering the promise - John Schiller



Towards cervical cancer elimination: the context of HPV Vaccination - Paul Bloem



Publications in scientific journals

Papillomavirus Research:

Manuscript on ‘Overcoming barriers in HPV vaccination and screening programs’

Vaccine:

HPV Immunization programs: Ensuring their sustainability and resilience.

Papilloma Virus Research:

The Role of healthcare providers in HPV Vaccination Programs- A meeting report



Papillomavirus Research

Volume 4, December 2017, Pages 45-53

[open access](#)



Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters ^a ✉, Marc Arbyn ^b, Marc Baay ^c, Xavier Bosch ^d, Silvia de Sanjosé ^{d, e}, Sharon Hanley ^f, Emilie Karafillakis ^g, Pier Luigi Lopalco ^h, Kevin G. Pollock ⁱ, Joanne Yarwood ^j, Pierre Van Damme ^a

Vaccine 36 (2018) 5219–5221



Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Commentary

HPV immunization programs: Ensuring their sustainability and resilience

Alex Vorsters ^{*}, Pierre Van Damme

Centre for the Evaluation of Vaccination, University of Antwerp, Belgium



Papillomavirus Research

Volume 8, December 2019, 100183



The role of healthcare providers in HPV vaccination programs – A meeting report



Publications in scientific journals

BMC Proceedings:

Prevention and control of HPV infection and HPV-related cancers in Colombia.

Vorsters et al. *BMC Proceedings* 2020, **14**(Suppl 9):8
<https://doi.org/10.1186/s12919-020-00192-2>

BMC Proceedings

MEETING REPORT

Open Access

Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report



Alex Vorsters^{1*}, Francesc Xavier Bosch^{2,3}, Paolo Bonanni⁴, Eduardo L. Franco⁵, Marc Baay⁶, Clarissa Simas⁷, Dur-e-Nayab Waheed¹, Carlos Castro⁸, Raul Murillo⁹, Lina Trujillo¹⁰, Carolina Wiesner¹⁰ and Nubia Muñoz¹⁰

From Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward Bogota, Colombia. 15-16 November 2018

Acta Dermatovenerologica

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Acta Dermatovenerol APA

Acta Dermatovenerologica
Alpina, Pannonica et Adriatica

2021;30:21-26
doi: 10.15570/actaapa.2021.5

Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening

Mario Poljak¹, Kate Cuschieri², Dur-e-Nayab Waheed³, Marc Baay⁴, Alex Vorsters^{3,5}

¹Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. ²Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian Scotland, Edinburgh, United Kingdom. ³Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Wilrijk, Belgium. ⁴Pg5 Epidemiology & Pharmacovigilance, Leuven, Belgium.





Online Technical Meeting

Reinforcing HPV Vaccination and Cervical Cancer Screening and Treatment

15 - 16 April, 2021
Antwerp, Belgium

BACKGROUND DOCUMENT

PRE-MEETING DRAFT

Meeting participants invited to provide input/comments

Dur-e-Nayab Waheed and Alex Vorsters
HPV Prevention & Control Board

Executive Secretariat, Vaccine and Infectious disease Institute, University of Antwerp, Campus Drie Eiken,
Universiteitsplein 1, 2610 Antwerp, Belgium.

Please note that this is a preliminary version of the background document. Any comments can be addressed to
navab.waheed@uantwerpen.be

Content

Introduction	1
Part 1: References based on a Pubmed search by Topic	2
Sustaining/Reinforcing HPV Vaccination	3
Potential Future Approaches for HPV Vaccination	8
Lessons learnt from Covid-19: Leveraging Opportunities for HPV Vaccination and Cervical cancer screening and treatment	17
Reinforcing/ sustaining Cervical Cancer Screening and Treatment	24
Part 2: Related Ouput	29
Part 3: Bibliography of speakers	41
Noel Brewer, University of North Carolina, United States	42
Carlos Castro, Colombian League Against Cancer, Colombia	42
Aimee Kreimer, National Cancer Institute, United States	43
Chantal Sauvageau, Université Laval, Québec, Canada	43
Heidi Larson, The London School of Hygiene & Tropical Medicine, Vaccine Confidence Project, United Kingdom	44
Partha Basu, International Agency for Research on Cancer (IARC), France	45
Mario Poljak, University of Ljubljana, Slovenia	46
Jack Cuzick, Wolfson Institute of Preventive Medicine in London, United Kingdom	47

Reinforcing HPV Vaccination and Cervical Cancer Screening and Treatment

15-16 April 2021

ANTWERP, BELGIUM

Meeting objectives (1):

- **Increasing access to HPV vaccination**
 - Discuss experiences and opportunities to sustain/reinforce/implement HPV vaccination in different regions across the world, in general and during the Covid-19 pandemic.
 - Discuss innovations that may help to achieve access targets such as, improved vaccination schedules, single dose, training and communication of Health Care Workers, etc.
 - Review successful country examples with increased access to vaccination and high vaccination coverage.
 - Discuss need for future research and trials.
 - Discuss lessons learnt from Covid-19 and how these opportunities can be leveraged to increase access to vaccination.



Meeting objectives (2):

- **Increasing access to cervical cancer screening and treatment**
 - Discuss experiences and opportunities to sustain/reinforce/implement screening and treatment programs across different regions in the world, in general and during the Covid-19 pandemic.
 - Discuss innovations that may help to achieve access targets such as, self-sampling, availability of HPV tests, point of care screening technology, artificial intelligence-based screening, digitally reaching out to women, etc.
 - Review successful country examples with increased access to screening and treatment.
 - Discuss need for future research and trials.
 - Discuss lessons learnt from Covid-19 and how to leverage these opportunities to increase access to cervical cancer screening and treatment.

